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Background: We explored the prevalence, clinical and physiologic correlates of pulmonary hy-
pertension (PH), and screening strategies in patients with severe emphysema evaluated for the
National Emphysema Treatment Trial (NETT).
Methods: Patients undergoing Doppler echocardiography (DE) and right heart catheterization
were included. Patients with mean pulmonary arterial pressure 25 mmHg (PH Group) were
compared to the remainder (non-PH Group).
Results: Of 797 patients, 302 (38%) had PH and 18 (2.2%) had severe PH. Compared to the non-PH
Group, patients with PH had lower % predicted FEV1 (p< 0.001), % predicted diffusion capacity for
carbon monoxide (pZ 0.006), and resting room air PaO2 (p < 0.001). By multivariate analysis,
elevated right ventricular systolic pressure, reduced resting room air PaO2, reduced post-
bronchodilator % predicted FEV1, and enlarged pulmonary arteries on computed tomographic scan
were the best predictors of PH. A strategy using % predicted FEV1, % predicted DLCO, PaO2, and
RVSP was predictive of the presence of pre-capillary PH and was highly predictive of its absence.of Pulmonary, Allergy, and Critical Care Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland,
; fax: þ1 216 445 1878.
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Pulmonary hemodynamics in emphysema 483Conclusions: Mildlyelevatedpulmonaryarterypressures are found ina significantproportionofpa-
tientswith severeemphysema.However, severePH is uncommon in theabsence of co-morbidities.
Simplenon-invasivetestsmaybehelpful in screeningpatients forpre-capillaryPH in severeemphy-
sema but none is reliably predictive of its presence.
ª 2013 Published by Elsevier Ltd.Introduction
The prevalence and clinical significance of pulmonary hy-
pertension (PH) in severe emphysema remains poorly
defined [1,2]. Several lines of evidence indicate that the
presence of PH has significant clinical implications in pa-
tients with emphysema. The presence of PH has been
associated with reduced functional capacity, increased risk
for hospitalization, and reduced survival among emphy-
sema patients (1,2). Right heart catheterization (RHC) is
the only way to conclusively make the diagnosis. Given the
low prevalence of PH in the overall emphysema population,
there is a need to identify non-invasive parameters that
may indicate a higher likelihood of the presence of PH to
allow clinicians to more accurately determine the need for
RHC. The NETT offers the distinctive advantages of a large
sample size in the context of a multi-center study, a group
of patients with emphysema, comprehensive character-
ization of the severity of emphysema, and careful exclusion
of any significant co-morbidities. Previous studies have
described the characteristics of NETT patients with PH in a
small subset of subjects [2,3]. The current paper expands
the analysis to all NETT subjects who underwent Doppler
echocardiography (DE) at baseline and presents an analysis
of the data regarding correlates and predictors of PH, based
on clinical and physiologic parameters, in the largest,
well-characterized population of emphysema patients
studied to date. Some of these results were previously
presented in abstract form at the American Thoracic Soci-
ety meeting [4].
Methods
The institutional review boards for each participating
NETT center (Cleveland Clinic IRB number 1653) approved
the protocols and all patients provided informed consent
before enrolling in the study. The NETT methods, and
inclusion and exclusion criteria have been published pre-
viously [5]. Our analysis included all patients undergoing
DE as part of evaluation for NETT eligibility. Patients
meeting inclusion criteria for NETT had advanced
emphysema based on pulmonary function (forced expira-
tory volume in one second [FEV1] 45% predicted, total
lung capacity 100% predicted, residual volume 150%
predicted) and computerized tomographic findings. Pa-
tients were excluded if they had medical co-morbidities
that were deemed to excessively increase their surgical
risk or decrease their expected functional benefit. Pa-
tients with known severe PH were excluded based on
history, physical examination, and prior cardiac testing
because PH has been shown to be a risk factor for peri-
operative morbidity and mortality [6].Resting two-dimensional DE was performed using stan-
dard techniques (Online supplement). Right heart cathe-
terization was performed when any of the following
conditions was met: the calculated right ventricular systolic
pressure (RVSP) by DE was 45 mmHg, the RVSP could not
be measured by DE (right atrial pressure or peak tricuspid
velocity could not be estimated from DE), the clinician felt
the patient was at an increased risk of having PH based on
clinical evaluation (Fig. 1), or the patient agreed to enroll
in the cardiovascular sub-study of NETT. Right heart cath-
eterization was performed with supplemental oxygen to
maintain arterial oxygen saturation >90%. All hemodynamic
measurements were the mean of three measurements at
end-expiration. Thermodilution cardiac output was re-
ported as the mean of at least five injections in which
agreement was within 20%. For the purposes of our analysis,
PH was defined as resting mean pulmonary artery pressure
(mPAP) 25 mmHg [7], pre-capillary PH as mPAP 25 mmHg
and pulmonary artery occlusion pressure (PAOP)
15 mmHg, post-capillary PH as mPAP 25 mmHg and PAOP
>15 mmHg, and severe PH was defined as a mPAP
>35 mmHg or mPAP 25 mmHg with pulmonary vascular
resistance 480 dynes/s/cm5 or cardiac index <2 L/min/m2
based on the Cologne Consensus definition [8].Statistical methods
Data were summarized using means and standard de-
viations for continuous data and frequency and percentage
for categorical data. For continuous measures, comparisons
between groups were made using Student’s t-test. Chi-
square tests of association were used to compare categor-
ical data; Fisher’s exact test was used when the assump-
tions for the chi-square test were not met. The association
between the DE estimates of RVSP and the right heart
catheterization systolic pulmonary arterial pressure (sPAP)
were measured using Spearman’s correlation coefficient.
Multivariable associations were measured using linear
regression for continuous outcomes and logistic regression
for binary outcomes. Explanatory variables were inspected
for multi-collinearity. Sensitivity, specificity, and positive
and negative predictive values were calculated.
For prediction of pre-capillary PH, variables were
considered for multivariable analysis if they showed a sta-
tistically significant difference by univariable analysis or if
they were felt to be clinically relevant. Modeling was per-
formed in 2 ways: 1) logistic regression with pre-capillary
PH as the outcome; 2) linear regression with mPAP as a
continuous numerical variable. The relative value of using
RVSP >40 mmHg and different parameters of pulmonary
function in predicting the presence of pre-capillary PH was
assessed by receiver operating curve (ROC) analyses. C-
Figure 1 Overall distribution of the study population PVR in dynes/s/cm5.
484 O.A. Minai et al.statistic analysis was also performed using these cut-points
to determine the additive value of various factors in pre-
dicting pre-capillary PH.
Results
Overall characteristics of the study population
Of 1857 patients who underwent DE, 797 (43%) underwent
right heart catheterization (Fig. 1). This group formed the
basis for our analysis. Of this group, 590 (74%) were even-
tually randomized into NETT and 207 (26%) were non-
randomized patients. Sixty two percent (N Z 495) had
mPAP <25 mmHg (no-PH Group) and 302 (38%) had mPAP
25 mmHg (PH Group). Of those with PH, 69% had pre-
capillary PH, 30% had post-capillary PH, and 104 (13%)
had pre-capillary PH with a pulmonary vascular resistance
>240 dynes/s/cm5 (Table 1, Fig. 1). Overall distributions
of pulmonary hemodynamics in the study population are
presented in the Online supplement Table 1 and Online
supplement Figs. 1 and 2. Almost 50% of patients with
pre-capillary PH had normal PVR and preserved CI.
Compared to those without PH, patients in the PH Group
had higher body mass index and more severely impaired
pulmonary function and oxygenation (Online supplement
Table 2). Despite these statistically significant differ-
ences, the mean differences were small and there was
substantial overlap between groups. Compared to patients
without PH, patients with PH were much more likely to
have a significantly higher % predicted residual volume (232
vs. 224; p Z 0.03) and frequently reported loud snoring
(36% of PH vs. 30% of non-PH group; p Z 0.01). Both thesedifferences were more prominent in patients with post-
capillary PH (Table 1). Compared to patients with post-
capillary PH, patients with pre-capillary PH had less se-
vere obstruction and lower diffusion capacity for carbon
monoxide (DLCO). There was a correlation between mPAP
and PAOP both in the overall group (r Z 0.540; CI [0.488,
0.588]; p < 0.001) and after excluding the post-capillary PH
population (i.e., including only those with no PH and pre-
capillary PH, r Z 0.393; CI (0.328, 0.454); p < 0.001]).
Severity of pulmonary hypertension
Analysis by quintiles of mPAP (Table 2 and Online
supplement Fig. 3) showed that an increase in mPAP was
associated with a decline in FEV1% predicted, DLCO % pre-
dicted, and partial pressure of oxygen (PaO2) and an in-
crease in partial pressure of carbon dioxide (PaCO2) and %
predicted residual volume. Eighteen patients (2.2%) had
severe PH (Table 3 Online supplement), only 1 of whom had
mPAP >35 mmHg (Table 1 of Online supplement). Those
with severe PH had lower FEV1 % predicted, DLCO % pre-
dicted, PaO2, and cardiac index compared to the non-PH
Group and patients with mild to moderate PH (Online
supplement Table 3).
Role of DE in screening for PH
In the 797 patients undergoing right heart catheterization,
the correlation between sPAP measured by DE and right
heart catheterization was moderate (Online supplement
Fig. 4). The sensitivity and specificity of DE for detecting
PH (defined as mPAP 25 mmHg) were 44% and 73%,
Table 1 Baseline characteristics of the study population by etiology of PH.
Characteristic N No PH [mean  SD] Pre-capillary PH
[mean  SD]
Post-capillary PH
[mean  SD]
No PH vs.
pre-capillary
PH; p value
No PH vs.
post-
capillary PH;
p value
Pre-capillary
PH vs. post-
capillary PH;
p value
N N N
Age (years) 796 495 67  6 209 67  6 92 66  6 0.64 0.11 0.23
Females, % 281 180 36 76 36 25 27 >0.99 0.09 0.12
Caucasian, % 761 474 96 198 95 89 97 0.56 >0.99 0.56
BMI (kg/m2) 796 495 24.5  4 209 24.8  3.9 92 25.5  4.4 0.35 <0.001 0.001
Loud snoring, %^ 254 150 30 68 32 36 39 0.91 0.29 0.30
Post-BD FEV1
(% predicted)
796 495 27.6  7 209 25.6  6.8 92 23.9  6.4 <0.001 <0.001 0.04
Post-BD FVC
(% predicted)
796 495 67  15 209 64  14.3 92 61.3  14 0.005 <0.001 0.1
Post-BD RV
(% predicted)
796 495 224  47 209 226  44 92 243  51 0.5 0.001 0.006
IC (liters-BTPS) 796 495 1.7  0.6 209 1.7  0.6 92 1.7  0.6 0.7 0.8 0.6
DLCO
(% predicted)
788 490 29  9 207 26  9 91 28  10 0.001 0.6 0.09
PEmax
(MEP cmH2O)
794 492 102  40 209 108  44 92 119  40 0.09 <0.001 0.03
PaO2 (mmHg) 796 495 65  11 209 61  9 92 61  8 <0.001 <0.001 0.6
PaCO2 (mmHg) 796 495 42  5 209 43  5.5 92 45  6 0.003 <0.001 0.004
mRAP (mmHg) 787 487 5.6  2.8 208 7.9  3.9 91 11.2  3.5 <0.001 <0.001 <0.001
mPAP (mmHg) 796 495 20.2  3.1 209 27.2  2.3 92 28.7  2.4
PAP systolic
(mmHg)
796 495 31  4.8 209 38.5  3.9 92 39  4.6 <0.001 <0.001 0.2
Pulse
pressure
(mmHg)
796 495 17  4.4 209 19  5 91 18  5 <0.001 0.2 0.01
PAOP (mmHg) 788 487 9.8  3.9 209 11.2  2.8 92 18.9  3
Cardiac index
(L/min/m2)
771 480 2.7  1.3 202 2.8  0.6 88 2.8  0.6 0.4 0.3 0.7
PVR
(dynes/s/cm5)
725 450 191  92 189 262  98 85 161  78 <0.001 0.002 <0.001
BMI: body mass index; BD: bronchodilator; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; TLC: total lung
capacity; RV: residual volume; IC: inspiratory capacity; MEP: maximum expiratory pressure; PaO2: partial pressure of oxygen; PaCO2:
partial pressure of carbon monoxide; mRAP: mean right atrial pressure; mPAP: mean pulmonary arterial pressure; PAOP: pulmonary
artery occlusion pressure; PVR: pulmonary vascular resistance.
NoPH Z mPAP <25 mmHg.
Pre-capillary PH Z mPAP 25 mmHg and PAOP 15 mmHg.
Post-capillary PH Z mPAP 25 mmHg and PAOP >15 mmHg.
Pulse pressure: PAP systolic e PAP diastolic.
C: Chi-square Test.
Other comparisons performed using Welch Two Sample T-test.
p^ Z 0.04 as a trend.
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negative predictive value of 68%. The bias (i.e., the dif-
ference between DE and right heart catheterization) as-
sesses the degree of inaccuracy of DE and was 10 mmHg
in 87 (26%) and 20 mmHg in 8 (2.4%) patients. The bias of
the sPAP estimation of RVSP appeared to have a linear
trend (Online supplement Fig. 4) and the correlation be-
tween sPAP and the bias was 0.28 (p < 0.001), indicating
that the bias had a tendency to increase as the sPAP
increased. A high proportion of patients with RVSP
36 mmHg had pre-capillary PH (Fig. 2 and Online
supplement Table 4).Univariable and multivariable prediction model for
PH in emphysema
Univariable and multivariable (Table 3) analysis was used to
predict the presence of PH (mPAP 25 mmHg) as a
dichotomous variable. In our population, RVSP, PaO2, FEV1
% predicted, and enlarged pulmonary arteries on computed
tomographic chest scanning (based on the radiologist’s
subjective designation) were associated with the presence
of PH. Table 4 presents the model for mPAP as a continuous
variable. With an overall model R2Z 0.44, only RVSP, PaO2,
Table 2 Baseline population characteristics by quintiles of mPAP.
Characteristic Quintile 1
N Z 162
Quintile 2
N Z 201
Quintile 3
N Z 129
Quintile 4
N Z 175
Quintile 5
N Z 129
P
mPAP (mmHg) 16.7  1.9 21.1  0.8 23.5  0.5 25.9  0.8 29.9  1.8
Age (years) 67  5 66  6 67  6 67  6 65  6 0.13A
BMI (kg/m2) 24  3.7 24.8  3.9 24.7  4 25.1  4 25.7  4.2 0.01A
Snore loudly, N (%) 50 (31) 56 (28) 42 (32.5) 49 (28) 56 (43) 0.006C
Use of oxygen when sleeping, N (%) 101 (62) 131 (65) 86 (67) 110 (63) 95 (74) 0.2C
Post-BD FEV1 (% predicted) 28.6  7.5 27.6  7.1 26.5  7.1 25.8  6.4 24.2  7.1 <0.001A
Post-BD FVC (% predicted) 69.6  15.7 66.8  14.9 65.6  15.9 63.9  13.7 61.9  15 <0.001A
Post-BD RV (% predicted) 223.6  45.4 222.8  46.3 227.9  52.5 224  44.3 242.8  49.2 0.002A
IC (liters-BTPS) 1.8  0.5 1.7  0.6 1.6  0.5 1.7  0.6 1.7  0.2 0.008A
DLCO (% predicted) 29.8  10.2 29.3  9.1 27  9 27.8  9 25.8  9 0.001A
PEmax (MEP cmH2O) 101.2  40.2 102.5  39.5 101.6  40 106.3  43.6 118.3  41.2 0.002A
PaO2 (mmHg) 64.5  11.6 64.9  10 64.9  10 61.9  9 59.8  8 <0.001A
PaCO2 (mmHg) 41.3  5.3 42.5  5.7 41.6  4.7 43.4  5.4 44.6  6.1 <0.001A
mRAP (mmHg) 4  2.3 5.9  2.4 7  2.8 8  3.6 10  4.3 <0.001A
PAP systolic (mmHg) 27  4 32  3.6 34.7  3.4 37  4 40.8  3.2
Pulse pressure (mmHg) 16  4.2 17.3  4.6 17.9  4.4 18.9  5.3 18.7  4.9
PAOP (mmHg) 7.6  3.3 10.2  3.5 11.9  3.8 12.6  4.2 14.9  4.8 <0.001A
Cardiac index (L/min/m2) 2.6  0.6 2.7  0.6 2.9  2.3 2.8  0.6 2.8  0.6 0.3A
PVR (dynes/s/cm5) 177  99 190  79 212  98 226  100 239  109 <0.001A
BMI: body mass index; BD: bronchodilator; FEV1: forced expiratory volume in the first second; FVC: forced vital capacity; TLC: total lung
capacity; RV: residual volume; IC: inspiratory capacity; MEP: maximum expiratory pressure; PaO2: partial pressure of oxygen; PaCO2:
partial pressure of carbon monoxide; mRAP: mean right atrial pressure; mPAP: mean pulmonary arterial pressure; PAOP: pulmonary
artery occlusion pressure; PVR: pulmonary vascular resistance.
Pulse pressure: PAP systolic e PAP diastolic.
A Z Analysis of variance; C Z Pearsons Chi-squared test.
486 O.A. Minai et al.ratio of % predicted residual volume to total lung capacity,
and enlarged pulmonary arteries on computed tomographic
chest scanning (based on the radiologist’s subjective
designation) were found to be significant predictors.
Practical screening strategies for pre-capillary PH
in emphysema
Using non-invasive parameters found to be significantly
different between the pre-capillary PH Group and no-PH
Group, analyses were performed to identify a simple and
practical screening strategy for pre-capillary PH in
emphysema patients. Approximately 19% of patients withFigure 2 Changing characteristics of pulmonary hemody-
namics by increasing RVSP.RVSP >40 mmHg and PaO2 <65 mmHg had pre-capillary PH
whereas only 1.8% of patients with RVSP <40 mmHg and
PaO2 >65 mmHg had pre-capillary PH. In addition, a ratio of
% predicted FEV1 to % predicted DLCO >1.4 had a high
specificity (0.84) for the presence of pre-capillary PH (Table
5 Online supplement).
Predictive cut-points for various risk factors were ob-
tained by univariable ROC analysis. The optimal threshold
for each measure was selected so as to jointly maximize
sensitivity and specificity (Online supplement Fig. 5). These
were used in the C-statistic analysis which showed that age,
measures of lung function severity, need for oxygen, and
RVSP measured by DE improved the predictive ability for
pre-capillary PH over any single factor (Fig. 3). A simple
model of likelihood of having pre-capillary PH using the 4
best non-invasive predictors (FEV1% predicted, DLCO % pre-
dicted, room air PaO2, and RVSP) using cut-offs identified by
ROC curves was also devised. Using this simple model, having
any 3 or more of these factors made the presence of pre-
capillary PH likely (Fig. 4 and Online supplement Table 6).
Only 5% of patients with none of the four risk factors were
found to have pre-capillary PH. Using FEV1% predicted/DLCO
% predicted in place of DLCO % predicted alone, did not in-
crease the predictive ability of the model.Discussion
This study showed that PH occurred in 38% of patients
with advanced emphysema who underwent right heart
Table 3 Univariable and multivariable prediction of pulmonary hypertension in the study population (N Z 797).
Univariable analysis
Variable N No PH PH OR (95% CI) P
N Mean  SD N Mean  SD
RVSP (mmHg) 779 484 31  5 295 38  7 1.28 (1.24, 1.34) <0.001
FEV1 (% predicted) 797 495 28  7 302 25  7 0.95 (0.93, 0.97) <0.001
DLCO (% predicted) 789 490 29  9 299 27  9 0.98 (0.96, 0.99) 0.006
PaO2 (mmHg) 797 495 65  11 302 61  9 0.96 (0.95, 0.98) <0.001
Supplemental O2 used with exertion 531
a 316 64% 215 72% 1.42 (1.05, 1.95) 0.02
Enlarged PA on CT (Yes) 125b 65 13% 60 20% 1.64 (1.12, 2.41) 0.01
Age 797 495 67  6 302 66  6 0.99 (0.96, 1.021 0.24
Multivariable analysis
Variable Level OR 95% Confidence interval P value
Intercept 0.00 (0, 0.03) <0.001
RVSP (mmHg) 7.86 (5.71, 11.08) <0.001
PaO2 (mmHg) 0.48 (0.35, 0.67) <0.001
FEV1 (% predicted) 0.48 (0.29, 0.81) 0.005
Enlarged PA on CT Yes vs. No 1.69 (1.03, 2.78) 0.03
 No PH: mPAP <25 mmHg; PH: mPAP 25 mmHg; OR: odds ratio; RVSP: right ventricular systolic pressure by Doppler echocardiography;
FEV1: forced expiratory volume in 1 s; PaO2: partial pressure for oxygen; DLCO: lung diffusion capacity for carbon monoxide; CT:
computed tomographic scan of the lungs.
a Data available for N Z 794.
b Data available for N Z 797.
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studies have shown a prevalence of PH from 35% to 91% in
patients with advanced COPD [1,9e11]. These studies have
been limited by several shortcomings including small sam-
ple size; single center studies with potential referral bias;
incomplete characterization of pulmonary function,
oxygenation, or hemodynamics; or the presence of co-
morbid illnesses that could alter pulmonary hemody-
namics. The current study is the largest report from a
multi-center study in well-characterized patients withTable 4 Linear regression model for predicting mPAP as a
continuous variable.
Level Beta 95% CI p Value
Intercept 8.2 2.15, 14.26 0.008
RVSP, mmHg 0.41 0.37, 0.44 <0.001
PaO2, mmHg 0.05 0.08, 0.02 <0.001
RV/TLC ratio,
% Predicted
1.91 0.47, 3.35 0.009
Enlarged
PA on CT (yes)
0.75 0.06, 1.44 0.03
FEV1, % Predicted 0.02 0.07, 0.04 0.55
DLCO, % Predicted 0.01 0.04, 0.03 0.74
Use of oxygen
when sleeping
Yes vs
No
0.02 0.61, 0.65 0.95
Age, years 0.01 0.04, 0.05 0.79
RVSP: right ventricular systolic pressure by Doppler echocardi-
ography; FEV1: forced expiratory volume in 1 s; PaO2: partial
pressure for oxygen; DLCO: lung diffusion capacity for carbon
monoxide; CT: computed tomographic scan of the lungs.advanced emphysema without significant cardiovascular
co-morbidities. Approximately 26% of our cohort was
comprised of patients screened with DE but not included in
NETT. It is reasonable to assume that patients not included
in NETT may have been screened less stringently to exclude
co-morbidities or may have been excluded precisely
because they had a co-morbid illness.
Due to inadequate hemodynamic characterization, pre-
vious reports have not attempted to determine the relative
prevalence of pre-capillary PH and post-capillary PH in this
population. We found that 26% of patients met the criteria
for pre-capillary PH and approximately 13% also had an
abnormally elevated PVR.
In keeping with prior reports [1,2,12,13], most patients
with PH in this series had only mild to moderate hemody-
namic derangement. In contrast to PH in patients with
other conditions [7], PH in emphysema patients was
accompanied by only mildly elevated pulmonary vascular
resistance without reduction in cardiac output. Very few
patients in this cohort met the definition of severe PH that
was proposed in the Cologne Consensus [8]. These results
are likely affected by several factors. Patients with more
significant PH (seen on DE) or severe resting hypoxemia or
hypercapnia were not included in NETT. Previous studies
have often included all patients referred for evaluation for
lung volume reduction surgery or lung transplantation
[1,9e12] and included patients with other co-morbidities.
Reports have shown that severe PH often occurs in
emphysema patients in the presence of co-morbidities [14]
and in those with upper lobe emphysema and lower lobe
fibrosis [15]. Both of these groups were systematically
excluded from NETT but were included in our study cohort.
Lastly, even though patients with RVSP >45 mmHg
Figure 3 Utilization of the C-statistic to assess the utility of
various factors in prediction of pre-capillary PH.
488 O.A. Minai et al.underwent RHC, some patients with elevated RVSP may
have been excluded by the investigator from undergoing
RHC thereby producing a ceiling effect. In view of these
limitations, the study may not give an accurate estimation
of the true prevalence of PH among patients with emphy-
sema and patients with more significant PH may be under-
represented in our report.
An interesting finding of our study was that almost 50% of
patients with pre-capillary PH had normal PVR and pre-
served CI. Our analysis also showed that there was aFigure 4 Performance of a simple prediction model for pre-
capillary PH in patients with emphysema. Factors: 1) FEV1
<27% predicted 2) DLCO <25% predicted 3) Room air PaO2
<65 mmHg 4) Right ventricular systolic pressure 40 mmHg.significant correlation between mPAP and PAOP even among
patients with pre-capillary PH. The significance of these
finding requires further investigation. It is noteworthy that
most medications used to treat PH are predominantly pul-
monary vasodilators and these findings may suggest reasons
for lack of efficacy of pulmonary vasodilators in treating PH
in the setting of COPD [16e18].
Our study confirms prior suggestions that the most
important correlates of abnormal pulmonary hemody-
namics in advanced emphysema are severity of pulmonary
function abnormalities and hypoxemia [1,2,12]. Post-
bronchodilator residual volume was significantly higher
among patients in the PH Group suggesting the importance
of air trapping in this population [19]. Air trapping may
result in increased pulmonary vascular resistance with a
corresponding reduction in pulmonary vascular compliance
[20] increasing right ventricular load. This would be espe-
cially true in COPD patients with underlying pulmonary
vascular remodeling [21]. A recent report suggests that the
degree of emphysema, as measured by computed tomo-
graphic scanning and degree of airflow obstruction, may be
associated with decreased left ventricular volumes [22]. It
is tempting to think that these factors may act synergisti-
cally to impair RV function in patients with emphysema and
hyperinflation.
This population was not screened for obstructive sleep
apnea and the PH group was more likely to report loud
snoring compared to the no-PH Group. This finding was
more prominent in the post-capillary PH group than in the
pre-capillary PH group. Quintile analysis showed that pa-
tients in the highest quintile of mPAP were most likely to
report loud snoring and had the highest BMI. In light of
previous evidence that shows a higher prevalence of PH in
patients with the ‘overlap syndrome’ (COPD with obstruc-
tive sleep apnea) [23] it may be that the higher body mass
index and loud snoring were markers of obstructive sleep
apnea in our population.
Because PH can limit functional capacity and survival in
COPD [1] and since confirmation of PH requires right heart
catheterization, there has been considerable interest in
optimizing the selection of right heart catheterization
candidates by non-invasive means. Our results offer pre-
diction models that performed well in this hypothesis-
generating study. Notably, when defining predictors of
mean PAP as a continuous variable, in addition to RVSP and
PaO2, having enlarged pulmonary arteries on CT scanning
was associated with elevated mean PAP. In contrast, pre-
vious studies [24e26] have reported variable results when
evaluating the utility of the finding of enlarged pulmonary
arteries in predicting whether or not the patient has PH.
However, a shortcoming of the current study is that pul-
monary artery enlargement was subjectively rather than
quantitatively defined as in earlier studies.
An important finding of our study was that RVSP was not
measurable in 58% of patients undergoing DE. Although our
findings confirm the inaccuracies of DE measurements in
estimating PAP in emphysema [1,12], several important
insights regarding the role of DE emerged. First, although
the degree of agreement between sPAP measured by DE
and right heart catheterization remained low throughout,
the closest agreement was seen for pressures between 35
and 45 mmHg. Second, the degree of inaccuracy increased
Pulmonary hemodynamics in emphysema 489with increasing pressures. Finally, even though DE had a
very low specificity and positive predictive value, most
patients with RVSP >36 mmHg were likely to have PH.
Previous studies have shown that a significant propor-
tion of patients with pulmonary arterial hypertension may
have a reduced DLCO out of proportion to compromise in
other parameters of pulmonary function [27,28], which
may be an early sign of risk for the subsequent develop-
ment of pulmonary arterial hypertension [28]. Our pre-
capillary PH Group had a slightly but significantly lower
DLCO compared to the no-PH Group. Given these findings,
we evaluated the utility of an FEV1 % predicted/DLCO %
predicted as a simple predictor of pre-capillary PH.
Similar to patients with scleroderma [29], an FEV1/DLCO
ratio >1.4 was found to be the best correlate of pre-
capillary PH, with a very high specificity but low sensi-
tivity. This approach requires further validation in an in-
dependent population.
Our C-statistic analysis suggests that even though an
elevated RVSP is the best predictor of increased likelihood
of pre-capillary PH, in patients with advanced emphysema,
demographic factors and measures of pulmonary function
and oxygenation can improve this predictive ability. Using a
combination of factors obtained from non-invasive tests,
we have proposed a relatively simple prediction model to
help clinicians determine the likelihood of having pre-
capillary PH in patients with COPD. These tests are per-
formed in most patients with COPD and would not add cost.
If validated, these parameters may be helpful for clinicians
as they determine candidacy for right heart catheterization
among patients with COPD since <5% of patients with no
risk factors and over 44% of those with 3 risk factors had
pre-capillary PH.
Several potential limitations of this study warrant
mention. First, because this is a hypothesis-generating
study, validation of the predictive models will require
replication in an independent study population. Second, as
noted, the model using enlargement of the pulmonary ar-
teries on computed tomographic scanning is limited by the
subjective nature of the rating. Third, the results of this
study are likely applicable only to a small proportion of all
patients with COPD seen in secondary or tertiary care
centers. Finally, as also noted above, the exclusion of pa-
tients deemed to have ‘severe’ PH in NETT may have biased
this analysis by a “ceiling effect.”
In conclusion, our analysis revealed that a significant
proportion of patients with advanced emphysema have
abnormal pulmonary hemodynamics and that these de-
rangements are typically mild to moderate. We found that
the most important correlates of abnormal pulmonary he-
modynamics in advanced emphysema are severity of pul-
monary function abnormalities and hypoxemia. Our findings
confirm the limitations and inaccuracies of DE measure-
ments in estimating PAP in emphysema and RVSP was not
measurable in 58% of patients. Although none of the non-
invasive parameters is reliable in predicting PH, we have
developed a relatively simple model (using FEV1% pre-
dicted, DLCO % predicted, room air PaO2, and RVSP) that
has the potential to increase the pre-test probability of
pre-capillary PH and may serve a useful function for clini-
cians as they determine candidacy for invasive testing
among their patients with COPD.Conflict of interest
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